<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00771563</url>
  </required_header>
  <id_info>
    <org_study_id>TOGA 0601</org_study_id>
    <secondary_id>EudraCT 2007-007696-16</secondary_id>
    <nct_id>NCT00771563</nct_id>
  </id_info>
  <brief_title>Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)</brief_title>
  <acronym>SYRINGES</acronym>
  <official_title>Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cisplatin Based First Line Chemotherapy: the SYRINGES Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: a number of recent phase III randomized trials have shown a survival benefit of a
      treatment with subcutaneous low-molecular weight heparin in patients with advanced solid
      malignancies. The survival advantages observed in the studies persist for months after the
      active treatment with LMWHs. Therefore these survival advantages are thought to be due to
      effects of LMWHs on tumor cell biology.

      First line treatment of advanced NSCLC patients with the Cisplatin + Docetaxel combination
      has been widely studied, and is amongst the most active treatments currently available. The
      occurrence of grade 3/4 thrombopenia in several phase III trials was in the 0-3% range,
      making it an ideal chemotherapy regimen to combine with LMWHs in the treatment of advanced
      NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: the aim of this study is to evaluate the potential beneficial antitumoral effect of
      LMWH enoxaparin in patients with locally advanced or metastatic NSCLC determined by the time
      to progression, the overall survival and the symptom control. LMWH will be added to a first
      line cisplatin-based chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>during chemotherapy and follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom control evaluated with the Lung Cancer Symptoms Scale (LCSS)</measure>
    <time_frame>during chemotherapy and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>during chemotherapy and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>during chemotherapy and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of total documented thromboembolic and hemorrhagic events</measure>
    <time_frame>during chemotherapy and follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety and tolerability</measure>
    <time_frame>during chemotherapy and follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy without LMWH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy with LMWH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin + docetaxel</intervention_name>
    <description>docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin + docetaxel + enoxaparin</intervention_name>
    <description>cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Platinol</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Clexane</other_name>
    <other_name>LMWH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced or metastatic NSCLC (stage IIIB or IV)

          -  Patients who are not candidates for radical combined modality treatments or high-dose
             radiation therapy

          -  At least one measurable lesion according to RECIST criteria

          -  Good performance status

          -  Adequate haematological, renal and liver function

          -  Written informed consent

        Exclusion Criteria:

          -  Previous chemotherapy for NSCLC

          -  Brain metastasis

          -  History of cerebral haemorrhage, neurosurgery within 3 previous months or surgery
             within the past 6 months

          -  Indication for anticoagulant therapy, thrombolytic therapy or antiplatelet therapy for
             cardiovascular disease

          -  Concomitant therapy with an anti-angiogenesis agent

          -  Contra-indication for LMWH

          -  Life expectancy of &lt; 3 months

          -  Serious concomitant systemic disease, uncontrolled arterial hypertension, active
             peptic ulcer or other condition which does not permit study treatment or follow-up
             required to comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul R Germonpre, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2008</study_first_submitted>
  <study_first_submitted_qc>October 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2008</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Ethisch Comité UZ Antwerpen</investigator_full_name>
    <investigator_title>Thoracale Oncologie Groep Antwerpen</investigator_title>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>Low Molecular Weight Heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

